{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T13:34:04Z","timestamp":1794317644324,"version":"4.9.0"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T00:00:00Z","timestamp":1644969600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005010","name":"associazione italiana per la ricerca sul cancro","doi-asserted-by":"publisher","award":["IG 2017 20286"],"award-info":[{"award-number":["IG 2017 20286"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"associazione italiana per la ricerca sul cancro","doi-asserted-by":"publisher","award":["MFAG 2020 23271"],"award-info":[{"award-number":["MFAG 2020 23271"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"associazione italiana per la ricerca sul cancro","doi-asserted-by":"publisher","award":["25364"],"award-info":[{"award-number":["25364"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005010","name":"associazione italiana per la ricerca sul cancro","doi-asserted-by":"publisher","award":["IG-20148"],"award-info":[{"award-number":["IG-20148"]}],"id":[{"id":"10.13039\/501100005010","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Ion channels are emerging as promising oncological targets. The potassium channels Kv1.3 and IKCa are highly expressed in the plasma membrane and mitochondria of human chronic lymphocytic leukemia (CLL) cells, compared to healthy lymphocytes. In vitro, inhibition of mitoKv1.3 by PAPTP was shown to kill ex vivo primary human CLL cells, while targeting IKCa with TRAM-34 decreased CLL cell proliferation.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Here we evaluated the effect of the above drugs in CLL cells from ibrutinib-resistant patients and in combination with Venetoclax, two drugs used in the clinical practice. The effects of the drugs were tested also in the E\u03bc-<jats:italic>TCL1<\/jats:italic> genetic CLL murine model, characterized by a lympho-proliferative disease reminiscent of aggressive human CLL. E\u03bc-<jats:italic>TCL1<\/jats:italic> mice showing overt disease state were treated with intraperitoneal injections of non-toxic 5\u2009nmol\/g PAPTP or 10\u2009nmol\/g TRAM-34 once a day and the number and percentage of pathological B cells (CD19<jats:sup>+<\/jats:sup>CD5<jats:sup>+<\/jats:sup>) in different, pathologically relevant body districts were determined.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>We show that Kv1.3 expression correlates with sensitivity of the human and mouse neoplastic cells to PAPTP. Primary CLL cells from ibrutinib-resistant patients could be killed with PAPTP and this drug enhanced the effect of Venetoclax, by acting on mitoKv1.3 of the inner mitochondrial membrane and triggering rapid mitochondrial changes and cytochrome c release. In vivo, after 2 week- therapy of E\u03bc-<jats:italic>TCL1<\/jats:italic> mice harboring distinct CLL clones, leukemia burden was reduced by more than 85%: the number and percentage of CLL B cells fall in the spleen and peritoneal cavity and in the peripheral blood, without signs of toxicity. Notably, CLL infiltration into liver and spleen and splenomegaly were also drastically reduced upon PAPTP treatment. In contrast, TRAM-34 did not exert any beneficial effect when administered in vivo to E\u03bc-<jats:italic>TCL1<\/jats:italic> mice at non-toxic concentration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Altogether, by comparing vehicle versus compound effect in different E\u03bc-<jats:italic>TCL1<\/jats:italic> animals bearing unique clones similarly to CLL patients, we conclude that PAPTP significantly reduced leukemia burden in CLL-relevant districts, even in animals with advanced stage of the disease. Our results thus identify PAPTP as a very promising drug for CLL treatment, even for the chemoresistant forms of the disease.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13046-022-02249-w","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T06:03:57Z","timestamp":1644991437000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Pharmacological modulation of Kv1.3 potassium channel selectively triggers pathological B lymphocyte apoptosis in vivo in a genetic CLL model"],"prefix":"10.1186","volume":"41","author":[{"given":"Filippo","family":"Severin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Urbani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatiana","family":"Varanita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Bachmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Azzolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Martini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Pizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo Paolo Dei","family":"Tos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Frezzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mattarei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa Sabrina","family":"Bertilaccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erich","family":"Gulbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Paradisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Zoratti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianpietro Carlo","family":"Semenzato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Leanza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Livio","family":"Trentin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3637-3947","authenticated-orcid":false,"given":"Ildiko","family":"Szab\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"issue":"12","key":"2249_CR1","doi-asserted-by":"publisher","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","volume":"111","author":"M Hallek","year":"2008","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the international workshop on chronic lymphocytic leukemia updating the National Cancer Institute-working group 1996 guidelines. Blood. 2008;111(12):5446\u201356.","journal-title":"Blood."},{"issue":"5","key":"2249_CR2","doi-asserted-by":"crossref","first-page":"716-.e1","DOI":"10.1016\/j.ccell.2017.10.015","volume":"32","author":"E Ten Hacken","year":"2017","unstructured":"Ten Hacken E, Gui\u00e8ze R, Wu CJ. SnapShot: chronic lymphocytic leukemia. Cancer Cell. 2017;32(5):716-.e1.","journal-title":"Cancer Cell"},{"issue":"6","key":"2249_CR3","doi-asserted-by":"publisher","first-page":"e434","DOI":"10.1038\/bcj.2016.41","volume":"6","author":"HJ Lee","year":"2016","unstructured":"Lee HJ, Gallardo M, Ma H, Zhang X, Larsson CA, Mejia A, et al. p53-independent ibrutinib responses in an E\u03bc-TCL1 mouse model demonstrates efficacy in high-risk CLL. Blood Cancer J. 2016;6(6):e434.","journal-title":"Blood Cancer J"},{"key":"2249_CR4","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.semcancer.2013.08.011","volume":"24","author":"JA Burger","year":"2014","unstructured":"Burger JA, Gribben JG. The microenvironment in chronic lymphocytic leukemia (CLL) and other B cell malignancies: insight into disease biology and new targeted therapies. Semin Cancer Biol. 2014;24:71\u201381.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"2249_CR5","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1038\/leu.2015.316","volume":"30","author":"SS Chen","year":"2016","unstructured":"Chen SS, Chang BY, Chang S, Tong T, Ham S, Sherry B, et al. BTK inhibition results in impaired CXCR4 chemokine receptor surface expression, signaling and function in chronic lymphocytic leukemia. Leukemia. 2016;30(4):833\u201343.","journal-title":"Leukemia."},{"issue":"4","key":"2249_CR6","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/1078-0432.CCR-15-2921","volume":"23","author":"NA Amin","year":"2017","unstructured":"Amin NA, Balasubramanian S, Saiya-Cork K, Shedden K, Hu N, Malek SN. Cell-intrinsic determinants of Ibrutinib-induced apoptosis in chronic lymphocytic leukemia. Clin Cancer Res. 2017;23(4):1049\u201359.","journal-title":"Clin Cancer Res"},{"issue":"39","key":"2249_CR7","doi-asserted-by":"publisher","first-page":"42130","DOI":"10.18632\/oncotarget.6239","volume":"6","author":"V Trimarco","year":"2015","unstructured":"Trimarco V, Ave E, Facco M, Chiodin G, Frezzato F, Martini V, et al. Cross-talk between chronic lymphocytic leukemia (CLL) tumor B cells and mesenchymal stromal cells (MSCs): implications for neoplastic cell survival. Oncotarget. 2015;6(39):42130\u201349.","journal-title":"Oncotarget."},{"issue":"4","key":"2249_CR8","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1513257","volume":"374","author":"AW Roberts","year":"2016","unstructured":"Roberts AW, Davids MS, Pagel JM, Kahl BS, Puvvada SD, Gerecitano JF, et al. Targeting BCL2 with Venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311\u201322.","journal-title":"N Engl J Med"},{"issue":"10","key":"2249_CR9","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41408-018-0131-2","volume":"8","author":"SA Parikh","year":"2018","unstructured":"Parikh SA. Chronic lymphocytic leukemia treatment algorithm 2018. Blood Cancer J. 2018;8(10):93.","journal-title":"Blood Cancer J"},{"key":"2249_CR10","doi-asserted-by":"crossref","unstructured":"F\u00fcrstenau M, Eichhorst B. Novel agents in chronic lymphocytic leukemia: new combination therapies and strategies to overcome resistance. Cancers. 2021;13(6):1336\u201342.","DOI":"10.3390\/cancers13061336"},{"issue":"1","key":"2249_CR11","doi-asserted-by":"publisher","first-page":"66","DOI":"10.2174\/092986709787002835","volume":"16","author":"A Arcangeli","year":"2009","unstructured":"Arcangeli A, Crociani O, Lastraioli E, Masi A, Pillozzi S, Becchetti A. Targeting ion channels in cancer: a novel frontier in antineoplastic therapy. Curr Med Chem. 2009;16(1):66\u201393.","journal-title":"Curr Med Chem"},{"issue":"1","key":"2249_CR12","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1038\/nrc3635","volume":"14","author":"LA Pardo","year":"2014","unstructured":"Pardo LA, Stuhmer W. The roles of K(+) channels in cancer. Nat Rev Cancer. 2014;14(1):39\u201348.","journal-title":"Nat Rev Cancer"},{"key":"2249_CR13","doi-asserted-by":"crossref","unstructured":"Leanza L, Manago A, Zoratti M, Gulbins E, Szabo I. Pharmacological targeting of ion channels for cancer therapy: in vivo evidences. Biochim Biophys Acta. 2016;1863:1385\u201397.","DOI":"10.1016\/j.bbamcr.2015.11.032"},{"key":"2249_CR14","doi-asserted-by":"crossref","unstructured":"Lastraioli E, Iorio J, Arcangeli A. Ion channel expression as promising cancer biomarker. Biochim Biophys Acta. 2015;1848:2685\u2013702.","DOI":"10.1016\/j.bbamem.2014.12.016"},{"issue":"1638","key":"2249_CR15","doi-asserted-by":"publisher","first-page":"20130094","DOI":"10.1098\/rstb.2013.0094","volume":"369","author":"D Urrego","year":"2014","unstructured":"Urrego D, Tomczak AP, Zahed F, Stuhmer W, Pardo LA. Potassium channels in cell cycle and cell proliferation. Philos Trans R Soc Lond Ser B Biol Sci. 2014;369(1638):20130094.","journal-title":"Philos Trans R Soc Lond Ser B Biol Sci"},{"issue":"2","key":"2249_CR16","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1083\/jcb.201404136","volume":"206","author":"X Huang","year":"2014","unstructured":"Huang X, Jan LY. Targeting potassium channels in cancer. J Cell Biol. 2014;206(2):151\u201362.","journal-title":"J Cell Biol"},{"issue":"4","key":"2249_CR17","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1111\/bph.12486","volume":"171","author":"I Azimi","year":"2014","unstructured":"Azimi I, Roberts-Thomson SJ, Monteith GR. Calcium influx pathways in breast cancer: opportunities for pharmacological intervention. Br J Pharmacol. 2014;171(4):945\u201360.","journal-title":"Br J Pharmacol"},{"issue":"1","key":"2249_CR18","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/j.1600-065X.2009.00816.x","volume":"231","author":"MD Cahalan","year":"2009","unstructured":"Cahalan MD, Chandy KG. The functional network of ion channels in T lymphocytes. Immunol Rev. 2009;231(1):59\u201387.","journal-title":"Immunol Rev"},{"issue":"2","key":"2249_CR19","doi-asserted-by":"publisher","first-page":"776","DOI":"10.4049\/jimmunol.173.2.776","volume":"173","author":"H Wulff","year":"2004","unstructured":"Wulff H, Knaus HG, Pennington M, Chandy KG. K+ channel expression during B cell differentiation: implications for immunomodulation and autoimmunity. J Immunol. 2004;173(2):776\u201386.","journal-title":"J Immunol"},{"issue":"4","key":"2249_CR20","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/leu.2014.37","volume":"28","author":"EM Grossinger","year":"2014","unstructured":"Grossinger EM, Weiss L, Zierler S, Rebhandl S, Krenn PW, Hinterseer E, et al. Targeting proliferation of chronic lymphocytic leukemia (CLL) cells through KCa3.1 blockade. Leukemia. 2014;28(4):954\u20138.","journal-title":"Leukemia."},{"issue":"3","key":"2249_CR21","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1159\/000430223","volume":"37","author":"I Szabo","year":"2015","unstructured":"Szabo I, Trentin L, Trimarco V, Semenzato G, Leanza L. Biophysical characterization and expression analysis of Kv1.3 Potassium Channel in primary human leukemic B cells. Cell Physiol Biochem. 2015;37(3):965\u201378.","journal-title":"Cell Physiol Biochem"},{"issue":"5","key":"2249_CR22","doi-asserted-by":"publisher","first-page":"683","DOI":"10.2174\/092986712798992093","volume":"19","author":"A Arcangeli","year":"2012","unstructured":"Arcangeli A, Pillozzi S, Becchetti A. Targeting ion channels in leukemias: a new challenge for treatment. Curr Med Chem. 2012;19(5):683\u201396.","journal-title":"Curr Med Chem"},{"key":"2249_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1146\/annurev-immunol-032414-112212","volume":"33","author":"S Feske","year":"2015","unstructured":"Feske S, Wulff H, Skolnik EY. Ion channels in innate and adaptive immunity. Annu Rev Immunol. 2015;33:291\u2013353.","journal-title":"Annu Rev Immunol"},{"issue":"14","key":"2249_CR24","doi-asserted-by":"publisher","first-page":"8151","DOI":"10.1073\/pnas.97.14.8151","volume":"97","author":"H Wulff","year":"2000","unstructured":"Wulff H, Miller MJ, Hansel W, Grissmer S, Cahalan MD, Chandy KG. Design of a potent and selective inhibitor of the intermediate-conductance Ca2+\u2212activated K+ channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A. 2000;97(14):8151\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"2249_CR25","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s00249-016-1143-0","volume":"45","author":"R Peruzzo","year":"2016","unstructured":"Peruzzo R, Biasutto L, Szabo I, Leanza L. Impact of intracellular ion channels on cancer development and progression. Eur Biophys J. 2016;45(7):685\u2013707.","journal-title":"Eur Biophys J"},{"issue":"S1","key":"2249_CR26","doi-asserted-by":"publisher","first-page":"63","DOI":"10.33594\/000000198","volume":"53","author":"M Bachmann","year":"2019","unstructured":"Bachmann M, Pontarin G, Szabo I. The contribution of mitochondrial ion channels to cancer development and progression. Cell Physiol Biochem. 2019;53(S1):63\u201378.","journal-title":"Cell Physiol Biochem"},{"issue":"2","key":"2249_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1152\/physrev.00021.2013","volume":"94","author":"I Szabo","year":"2014","unstructured":"Szabo I, Zoratti M. Mitochondrial channels: ion fluxes and more. Physiol Rev. 2014;94(2):519\u2013608.","journal-title":"Physiol Rev"},{"issue":"39","key":"2249_CR28","doi-asserted-by":"publisher","first-page":"14861","DOI":"10.1073\/pnas.0804236105","volume":"105","author":"I Szabo","year":"2008","unstructured":"Szabo I, Bock J, Grassme H, Soddemann M, Wilker B, Lang F, et al. Mitochondrial potassium channel Kv1.3 mediates Bax-induced apoptosis in lymphocytes. Proc Natl Acad Sci U S A. 2008;105(39):14861\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2249_CR29","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.ccell.2017.03.003","volume":"31","author":"L Leanza","year":"2017","unstructured":"Leanza L, Romio M, Becker KA, Azzolini M, Trentin L, Manago A, et al. Direct pharmacological targeting of a mitochondrial Ion Channel selectively kills tumor cells in vivo. Cancer Cell. 2017;31(4):516\u201331.e10.","journal-title":"Cancer Cell"},{"issue":"5","key":"2249_CR30","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1124\/mol.105.015669","volume":"68","author":"A Schmitz","year":"2005","unstructured":"Schmitz A, Sankaranarayanan A, Azam P, Schmidt-Lassen K, Homerick D, Hansel W, et al. Design of PAP-1, a selective small molecule Kv1.3 blocker, for the suppression of effector memory T cells in autoimmune diseases. Mol Pharmacol. 2005;68(5):1254\u201370.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"2249_CR31","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1159\/000480643","volume":"25","author":"E Venturini","year":"2017","unstructured":"Venturini E, Leanza L, Azzolini M, Kadow S, Mattarei A, Weller M, et al. Targeting the Potassium Channel Kv1.3 kills Glioblastoma cells. Neuro-Signals. 2017;25(1):26\u201338.","journal-title":"Neuro-Signals."},{"issue":"8","key":"2249_CR32","doi-asserted-by":"publisher","first-page":"1782","DOI":"10.1038\/leu.2013.56","volume":"27","author":"L Leanza","year":"2013","unstructured":"Leanza L, Trentin L, Becker KA, Frezzato F, Zoratti M, Semenzato G, et al. Clofazimine, Psora-4 and PAP-1, inhibitors of the potassium channel Kv1.3, as a new and selective therapeutic strategy in chronic lymphocytic leukemia. Leukemia. 2013;27(8):1782\u20135.","journal-title":"Leukemia."},{"issue":"10","key":"2249_CR33","doi-asserted-by":"publisher","first-page":"6955","DOI":"10.1073\/pnas.102181599","volume":"99","author":"R Bichi","year":"2002","unstructured":"Bichi R, Shinton SA, Martin ES, Koval A, Calin GA, Cesari R, et al. Human chronic lymphocytic leukemia modeled in mouse by targeted TCL1 expression. Proc Natl Acad Sci U S A. 2002;99(10):6955\u201360.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2249_CR34","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1182\/blood-2005-12-011213","volume":"108","author":"AJ Johnson","year":"2006","unstructured":"Johnson AJ, Lucas DM, Muthusamy N, Smith LL, Edwards RB, De Lay MD, et al. Characterization of the TCL-1 transgenic mouse as a preclinical drug development tool for human chronic lymphocytic leukemia. Blood. 2006;108(4):1334\u20138.","journal-title":"Blood."},{"issue":"31","key":"2249_CR35","doi-asserted-by":"publisher","first-page":"11713","DOI":"10.1073\/pnas.0604564103","volume":"103","author":"XJ Yan","year":"2006","unstructured":"Yan XJ, Albesiano E, Zanesi N, Yancopoulos S, Sawyer A, Romano E, et al. B cell receptors in TCL1 transgenic mice resemble those of aggressive, treatment-resistant human chronic lymphocytic leukemia. Proc Natl Acad Sci U S A. 2006;103(31):11713\u20138.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"18","key":"2249_CR36","doi-asserted-by":"publisher","first-page":"3537","DOI":"10.1182\/blood-2009-12-258814","volume":"116","author":"C Scielzo","year":"2010","unstructured":"Scielzo C, Bertilaccio MT, Simonetti G, Dagklis A, ten Hacken E, Fazi C, et al. HS1 has a central role in the trafficking and homing of leukemic B cells. Blood. 2010;116(18):3537\u201346.","journal-title":"Blood."},{"key":"2249_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.semcancer.2018.02.001","volume":"51","author":"L Mansouri","year":"2018","unstructured":"Mansouri L, Wierzbinska JA, Plass C, Rosenquist R. Epigenetic deregulation in chronic lymphocytic leukemia: clinical and biological impact. Semin Cancer Biol. 2018;51:1\u201311.","journal-title":"Semin Cancer Biol"},{"issue":"19","key":"2249_CR38","doi-asserted-by":"publisher","first-page":"4656","DOI":"10.1182\/blood-2008-09-175430","volume":"113","author":"DM Lucas","year":"2009","unstructured":"Lucas DM, Edwards RB, Lozanski G, West DA, Shin JD, Vargo MA, et al. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo. Blood. 2009;113(19):4656\u201366.","journal-title":"Blood."},{"issue":"4","key":"2249_CR39","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/leu.2017.321","volume":"32","author":"VK Patel","year":"2018","unstructured":"Patel VK, Lamothe B, Ayres ML, Gay J, Cheung JP, Balakrishnan K, et al. Pharmacodynamics and proteomic analysis of acalabrutinib therapy: similarity of on-target effects to ibrutinib and rationale for combination therapy. Leukemia. 2018;32(4):920\u201330.","journal-title":"Leukemia."},{"issue":"9","key":"2249_CR40","doi-asserted-by":"publisher","first-page":"2520","DOI":"10.1158\/0008-5472.CAN-13-2033","volume":"74","author":"W Fiskus","year":"2014","unstructured":"Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014;74(9):2520\u201332.","journal-title":"Cancer Res"},{"issue":"10","key":"2249_CR41","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3324\/haematol.2018.209981","volume":"104","author":"L Patrussi","year":"2019","unstructured":"Patrussi L, Capitani N, Ulivieri C, Manganaro N, Granai M, Cattaneo F, et al. p66Shc deficiency in the E\u03bc-TCL1 mouse model of chronic lymphocytic leukemia enhances leukemogenesis by altering the chemokine receptor landscape. Haematologica. 2019;104(10):2040\u201352.","journal-title":"Haematologica."},{"key":"2249_CR42","doi-asserted-by":"publisher","first-page":"592205","DOI":"10.3389\/fonc.2020.592205","volume":"10","author":"MV Haselager","year":"2020","unstructured":"Haselager MV, Kater AP, Eldering E. Proliferative signals in chronic lymphocytic leukemia; what are we missing? Front Oncol. 2020;10:592205.","journal-title":"Front Oncol"},{"key":"2249_CR43","doi-asserted-by":"publisher","first-page":"612244","DOI":"10.3389\/fimmu.2020.612244","volume":"11","author":"E Vlachonikola","year":"2020","unstructured":"Vlachonikola E, Stamatopoulos K, Chatzidimitriou A. T cells in chronic lymphocytic leukemia: a two-edged sword. Front Immunol. 2020;11:612244.","journal-title":"Front Immunol"},{"issue":"25","key":"2249_CR44","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","volume":"131","author":"M Hallek","year":"2018","unstructured":"Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, D\u00f6hner H, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745\u201360.","journal-title":"Blood."},{"issue":"11","key":"2249_CR45","doi-asserted-by":"publisher","first-page":"3089","DOI":"10.1002\/ijc.32383","volume":"145","author":"F Frezzato","year":"2019","unstructured":"Frezzato F, Raggi F, Martini V, Severin F, Trimarco V, Visentin A, et al. HSP70\/HSF1 axis, regulated via a PI3K\/AKT pathway, is a druggable target in chronic lymphocytic leukemia. Int J Cancer. 2019;145(11):3089\u2013100.","journal-title":"Int J Cancer"},{"key":"2249_CR46","doi-asserted-by":"crossref","unstructured":"Severin F, Frezzato F, Visentin A, Martini V, Trimarco V, Carraro S, et al. In chronic lymphocytic leukemia the JAK2\/STAT3 pathway is constitutively activated and its inhibition leads to CLL cell death unaffected by the protective bone marrow microenvironment. Cancers. 2019;11(12):1939.","DOI":"10.3390\/cancers11121939"},{"key":"2249_CR47","doi-asserted-by":"publisher","first-page":"101705","DOI":"10.1016\/j.redox.2020.101705","volume":"37","author":"R Peruzzo","year":"2020","unstructured":"Peruzzo R, Mattarei A, Azzolini M, Becker-Flegler KA, Romio M, Rigoni G, et al. Insight into the mechanism of cytotoxicity of membrane-permeant psoralenic Kv1.3 channel inhibitors by chemical dissection of a novel member of the family. Redox Biol. 2020;37:101705.","journal-title":"Redox Biol"},{"issue":"12","key":"2249_CR48","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nrd4002","volume":"12","author":"C Gorrini","year":"2013","unstructured":"Gorrini C, Harris IS, Mak TW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12(12):931\u201347.","journal-title":"Nat Rev Drug Discov"},{"issue":"31","key":"2249_CR49","doi-asserted-by":"publisher","first-page":"5394","DOI":"10.2174\/092986712803833281","volume":"19","author":"L Leanza","year":"2012","unstructured":"Leanza L, Zoratti M, Gulbins E, Szabo I. Induction of apoptosis in macrophages via Kv1.3 and Kv1.5 potassium channels. Curr Med Chem. 2012;19(31):5394\u2013404.","journal-title":"Curr Med Chem"},{"issue":"4","key":"2249_CR50","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1002\/1097-0142(19870815)60:4<827::AID-CNCR2820600419>3.0.CO;2-A","volume":"60","author":"M Barcos","year":"1987","unstructured":"Barcos M, Lane W, Gomez GA, Han T, Freeman A, Preisler H, et al. An autopsy study of 1206 acute and chronic leukemias (1958 to 1982). Cancer. 1987;60(4):827\u201337.","journal-title":"Cancer."},{"issue":"1","key":"2249_CR51","first-page":"72","volume":"26","author":"HB Lee","year":"1985","unstructured":"Lee HB, Blaufox MD. Blood volume in the rat. J Nucl Med. 1985;26(1):72\u20136.","journal-title":"J Nucl Med"},{"key":"2249_CR52","doi-asserted-by":"crossref","unstructured":"Ten Hacken E, Valentin R, Regis FFD, Sun J, Yin S, Werner L, et al. Splicing modulation sensitizes chronic lymphocytic leukemia cells to venetoclax by remodeling mitochondrial apoptotic dependencies. JCI Insight. 2018;3(19):e121438.","DOI":"10.1172\/jci.insight.121438"},{"issue":"8","key":"2249_CR53","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/s41419-020-02910-2","volume":"11","author":"A Muenchow","year":"2020","unstructured":"Muenchow A, Weller S, Hinterleitner C, Malenke E, Bugl S, Wirths S, et al. The BCL-2 selective inhibitor ABT-199 sensitizes soft tissue sarcomas to proteasome inhibition by a concerted mechanism requiring BAX and NOXA. Cell Death Dis. 2020;11(8):701.","journal-title":"Cell Death Dis"},{"issue":"7","key":"2249_CR54","doi-asserted-by":"publisher","first-page":"890","DOI":"10.1158\/2159-8290.CD-19-0117","volume":"9","author":"X Chen","year":"2019","unstructured":"Chen X, Glytsou C, Zhou H, Narang S, Reyna DE, Lopez A, et al. Targeting mitochondrial structure sensitizes acute myeloid leukemia to Venetoclax treatment. Cancer Discovery. 2019;9(7):890\u2013909.","journal-title":"Cancer Discovery"},{"key":"2249_CR55","doi-asserted-by":"publisher","first-page":"411","DOI":"10.3389\/fonc.2018.00411","volume":"8","author":"G Galicia-V\u00e1zquez","year":"2018","unstructured":"Galicia-V\u00e1zquez G, Aloyz R. Ibrutinib resistance is reduced by an inhibitor of fatty acid oxidation in primary CLL lymphocytes. Front Oncol. 2018;8:411.","journal-title":"Front Oncol"},{"issue":"4","key":"2249_CR56","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.ccr.2012.08.014","volume":"22","author":"P Caro","year":"2012","unstructured":"Caro P, Kishan AU, Norberg E, Stanley IA, Chapuy B, Ficarro SB, et al. Metabolic signatures uncover distinct targets in molecular subsets of diffuse large B cell lymphoma. Cancer Cell. 2012;22(4):547\u201360.","journal-title":"Cancer Cell"},{"key":"2249_CR57","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3389\/fonc.2020.00067","volume":"10","author":"K Gemenetzi","year":"2020","unstructured":"Gemenetzi K, Agathangelidis A, Zaragoza-Infante L, Sofou E, Papaioannou M, Chatzidimitriou A, et al. B cell receptor Immunogenetics in B cell lymphomas: immunoglobulin genes as key to ontogeny and clinical decision making. Front Oncol. 2020;10:67.","journal-title":"Front Oncol"},{"issue":"21","key":"2249_CR58","doi-asserted-by":"publisher","first-page":"18528","DOI":"10.1074\/jbc.M200592200","volume":"277","author":"GA Smith","year":"2002","unstructured":"Smith GA, Tsui HW, Newell EW, Jiang X, Zhu XP, Tsui FW, et al. Functional up-regulation of HERG K+ channels in neoplastic hematopoietic cells. J Biol Chem. 2002;277(21):18528\u201334.","journal-title":"J Biol Chem"},{"key":"2249_CR59","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drup.2015.06.002","volume":"21-22","author":"A Arcangeli","year":"2015","unstructured":"Arcangeli A, Becchetti A. Novel perspectives in cancer therapy: targeting ion channels. Drug Resist Updates. 2015;21-22:11\u20139.","journal-title":"Drug Resist Updates"},{"key":"2249_CR60","doi-asserted-by":"crossref","unstructured":"Comes N, Bielanska J, Vallejo-Gracia A, Serrano-Albarr\u00e1s A, Marruecos L, G\u00f3mez D, et al. The voltage-dependent K+ channels Kv1.3 and Kv1.5 in human cancer. Front Physiol. 2013;4:283.","DOI":"10.3389\/fphys.2013.00283"},{"issue":"1","key":"2249_CR61","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s40880-019-0412-6","volume":"39","author":"L Dong","year":"2019","unstructured":"Dong L, Neuzil J. Targeting mitochondria as an anticancer strategy. Cancer Commun. 2019;39(1):63.","journal-title":"Cancer Commun"},{"key":"2249_CR62","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/164_2017_12","volume":"249","author":"F Arruga","year":"2018","unstructured":"Arruga F, Deaglio S. Mechanisms of resistance to targeted therapies in chronic lymphocytic leukemia. Handb Exp Pharmacol. 2018;249:203\u201329.","journal-title":"Handb Exp Pharmacol"},{"key":"2249_CR63","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3389\/fphar.2020.00489","volume":"11","author":"D Palme","year":"2020","unstructured":"Palme D, Misovic M, Ganser K, Klumpp L, Salih HR, Zips D, et al. hERG K(+) channels promote survival of irradiated leukemia cells. Front Pharmacol. 2020;11:489.","journal-title":"Front Pharmacol"},{"issue":"6","key":"2249_CR64","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1038\/leu.2014.26","volume":"28","author":"S Pillozzi","year":"2014","unstructured":"Pillozzi S, Accordi B, Rebora P, Serafin V, Valsecchi MG, Basso G, et al. Differential expression of hERG1A and hERG1B genes in pediatric acute lymphoblastic leukemia identifies different prognostic subgroups. Leukemia. 2014;28(6):1352\u20135.","journal-title":"Leukemia."},{"issue":"9349","key":"2249_CR65","doi-asserted-by":"publisher","first-page":"1935","DOI":"10.1016\/S0140-6736(02)11917-9","volume":"360","author":"U Thunberg","year":"2002","unstructured":"Thunberg U, Tobin G, Johnson A, S\u00f6derberg O, Padyukov L, Hultdin M, et al. Polymorphism in the P2X7 receptor gene and survival in chronic lymphocytic leukaemia. Lancet (London, England). 2002;360(9349):1935\u20139.","journal-title":"Lancet (London, England)"},{"key":"2249_CR66","doi-asserted-by":"publisher","first-page":"26280","DOI":"10.1038\/srep26280","volume":"6","author":"E Salaro","year":"2016","unstructured":"Salaro E, Rambaldi A, Falzoni S, Amoroso FS, Franceschini A, Sarti AC, et al. Involvement of the P2X7-NLRP3 axis in leukemic cell proliferation and death. Sci Rep. 2016;6:26280.","journal-title":"Sci Rep"},{"issue":"50","key":"2249_CR67","doi-asserted-by":"publisher","first-page":"18078","DOI":"10.1073\/pnas.1411390111","volume":"111","author":"E Hondares","year":"2014","unstructured":"Hondares E, Brown MA, Musset B, Morgan D, Cherny VV, Taubert C, et al. Enhanced activation of an amino-terminally truncated isoform of the voltage-gated proton channel HVCN1 enriched in malignant B cells. Proc Natl Acad Sci U S A. 2014;111(50):18078\u201383.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2249_CR68","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s40425-019-0591-3","volume":"7","author":"M Debant","year":"2019","unstructured":"Debant M, Burgos M, Hemon P, Buscaglia P, Fali T, Melayah S, et al. STIM1 at the plasma membrane as a new target in progressive chronic lymphocytic leukemia. J Immunother Cancer. 2019;7(1):111.","journal-title":"J Immunother Cancer"},{"key":"2249_CR69","doi-asserted-by":"crossref","unstructured":"Szabo I, Zoratti M, Biasutto L. Targeting mitochondrial ion channels for cancer therapy. Redox Biol. 2021;42:101846.","DOI":"10.1016\/j.redox.2020.101846"},{"key":"2249_CR70","doi-asserted-by":"publisher","first-page":"e809","DOI":"10.1038\/cddis.2013.316","volume":"4","author":"T Prezma","year":"2013","unstructured":"Prezma T, Shteinfer A, Admoni L, Raviv Z, Sela I, Levi I, et al. VDAC1-based peptides: novel pro-apoptotic agents and potential therapeutics for B-cell chronic lymphocytic leukemia. Cell Death Dis. 2013;4:e809.","journal-title":"Cell Death Dis"},{"key":"2249_CR71","doi-asserted-by":"crossref","unstructured":"Tibaldi E, Federti E, Matte A, Iatcenko I, Wilson AB, Riccardi V, et al. Oxidation impacts the intracellular signaling machinery in hematological disorders. Antioxidants (Basel, Switzerland). 2020;9(4):353.","DOI":"10.3390\/antiox9040353"},{"issue":"2","key":"2249_CR72","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1016\/j.cell.2018.02.048","volume":"173","author":"G Xiao","year":"2018","unstructured":"Xiao G, Chan LN, Klemm L, Braas D, Chen Z, Geng H, et al. B-cell-specific diversion of glucose carbon utilization reveals a unique vulnerability in B cell malignancies. Cell. 2018;173(2):470\u201384.e18.","journal-title":"Cell."},{"issue":"3","key":"2249_CR73","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1038\/ncb2432","volume":"14","author":"W Zhang","year":"2012","unstructured":"Zhang W, Trachootham D, Liu J, Chen G, Pelicano H, Garcia-Prieto C, et al. Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia. Nat Cell Biol. 2012;14(3):276\u201386.","journal-title":"Nat Cell Biol"},{"issue":"8","key":"2249_CR74","doi-asserted-by":"publisher","first-page":"1812","DOI":"10.1038\/leu.2012.63","volume":"26","author":"M Sivina","year":"2012","unstructured":"Sivina M, Hartmann E, Vasyutina E, Boucas JM, Breuer A, Keating MJ, et al. Stromal cells modulate TCL1 expression, interacting AP-1 components and TCL1-targeting micro-RNAs in chronic lymphocytic leukemia. Leukemia. 2012;26(8):1812\u201320.","journal-title":"Leukemia."},{"issue":"8","key":"2249_CR75","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/j.celrep.2019.07.050","volume":"28","author":"R Costa","year":"2019","unstructured":"Costa R, Peruzzo R, Bachmann M, Monta GD, Vicario M, Santinon G, et al. Impaired mitochondrial ATP production Downregulates Wnt signaling via ER stress induction. Cell Rep. 2019;28(8):1949\u201360.e6.","journal-title":"Cell Rep"},{"issue":"24","key":"2249_CR76","doi-asserted-by":"publisher","first-page":"4701","DOI":"10.1111\/bph.13949","volume":"174","author":"P Janovsk\u00e1","year":"2017","unstructured":"Janovsk\u00e1 P, Bryja V. Wnt signaling pathways in chronic lymphocytic leukaemia and B-cell lymphomas. Br J Pharmacol. 2017;174(24):4701\u201315.","journal-title":"Br J Pharmacol"},{"issue":"12","key":"2249_CR77","doi-asserted-by":"publisher","first-page":"2363","DOI":"10.1038\/jcbfm.2011.101","volume":"31","author":"YJ Chen","year":"2011","unstructured":"Chen YJ, Raman G, Bodendiek S, O'Donnell ME, Wulff H. The KCa3.1 blocker TRAM-34 reduces infarction and neurological deficit in a rat model of ischemia\/reperfusion stroke. J Cereb Blood Flow Metab. 2011;31(12):2363\u201374.","journal-title":"J Cereb Blood Flow Metab"},{"issue":"21","key":"2249_CR78","doi-asserted-by":"publisher","first-page":"30781","DOI":"10.18632\/oncotarget.8761","volume":"7","author":"G D'Alessandro","year":"2016","unstructured":"D'Alessandro G, Grimaldi A, Chece G, Porzia A, Esposito V, Santoro A, et al. KCa3.1 channel inhibition sensitizes malignant gliomas to temozolomide treatment. Oncotarget. 2016;7(21):30781\u201396.","journal-title":"Oncotarget."},{"issue":"2","key":"2249_CR79","doi-asserted-by":"publisher","first-page":"e2594","DOI":"10.1038\/cddis.2017.6","volume":"8","author":"D Bauer","year":"2017","unstructured":"Bauer D, Werth F, Nguyen HA, Kiecker F, Eberle J. Critical role of reactive oxygen species (ROS) for synergistic enhancement of apoptosis by vemurafenib and the potassium channel inhibitor TRAM-34 in melanoma cells. Cell Death Dis. 2017;8(2):e2594.","journal-title":"Cell Death Dis"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02249-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-022-02249-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-022-02249-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,24]],"date-time":"2022-10-24T17:12:36Z","timestamp":1666631556000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-022-02249-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":79,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2249"],"URL":"https:\/\/doi.org\/10.1186\/s13046-022-02249-w","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]},"assertion":[{"value":"24 July 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Experiments on mice and human CLL B cells were conducted according to the Local Ethical Committee at the University of Padua and National Agency, and with the supervision of the Central Veterinary Service of the University of Padova (in compliance with Italian Law DL 116\/92 and further modifications, embodying UE directive 86\/609), authorizations n. 4218\/A0\/17 and 111\/2017-PR.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"64"}}